Navigation Links
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Date:2/7/2013

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012  after the NASDAQ Market closes on Thursday, February 14, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six months ended December 31, 2012 represent a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Conference call and webcast details:

Date: February 14, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 409002

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several research molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE PHARMACYCLICS/ ACCOUNTS PAYABLE
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... , Dec. 6, 2016  BTL Aesthetics today ... that its BTL Vanquish ME device was effectively ... delivery to the targeted tissue. The result: Significantly ... higher, with BTL Vanquish ME versus BTL Vanquish. ... physician network and their patients with the most ...
(Date:12/6/2016)... 6, 2016   Sienna Biopharmaceuticals, Inc. ... and aesthetics company, today announced it has ... pharmaceutical company focused on developing first-in-class topical ... psoriasis, atopic dermatitis and pruritus (itch). Under ... make an undisclosed upfront payment in cash ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly ... team of three acupuncturists to help patients realize their family building goals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from ... inspire the reader to be aware of God's direction in their lives. “Walking With ... Smith, retired teacher and active church leader. , Sanford says, “I enjoy ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
(Date:12/7/2016)... York (PRWEB) , ... December 07, 2016 , ... "Hacking ... at Yale had described him as 'a genius.'" Thus begins "Margaret in Berlin," Book ... Rhyse and published by Wyston Books, Inc. These novels narrate the lives ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease are ... serious health problems, such as cardiovascular illness, according to research cited in a ... Periodontics & Dental Implant Center notes that the correlation between periodontal disease and ...
Breaking Medicine News(10 mins):